Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5088875 | 0.77 | HSD11B1 (0.59) | DDB1CRBNHSD11B1KMT2ANPC1 | |
| SCHEMBL6734403 | 0.74 | HSD11B1 (0.56) | DDB1CRBNHSD11B1KMT2ANPC1 | |
| SCHEMBL11684304 | 0.74 | KMT2A (0.48) | HSD11B1KMT2ANPC1ALDH1A1RAB9A | |
| SCHEMBL6879875 | 0.73 | SRD5A1 (0.42) | DDB1CRBN | |
| SCHEMBL29016897 | 0.73 | DDB1 (0.61) | DDB1CRBNHSD11B1KMT2A | |
| SCHEMBL28995160 | 0.72 | DRD2 (0.46) | KMT2ANPC1ALDH1A1RAB9ATSHR | |
| SCHEMBL30489343 | 0.72 | DRD2 (0.46) | KMT2ANPC1ALDH1A1RAB9ATSHR | |
| SCHEMBL9800237 | 0.71 | KMT2A (0.69) | DDB1CRBNKMT2ATSHRMEN1 | |
| SCHEMBL28942364 | 0.70 | HSD11B1 (0.59) | DDB1CRBNHSD11B1KMT2ANPC1 | |
| SCHEMBL5106732 | 0.70 | HSD11B1 (0.59) | DDB1CRBNHSD11B1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293702-A1 | QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-09-21 | — | — | US | disclosed |
| US-9150414-B2 | Nanocomposite and dispersion comprising the same | KABUSHIKI KAISHA TOYOTA CHUO KENKYUSHO (JP) | 2015-10-06 | — | — | US | disclosed |
| US-20120053288-A1 | NANOCOMPOSITE AND DISPERSION COMPRISING THE SAME | KABUSHIKI KAISHA TOYOTA CHUO KENKYUSHO (JP) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293702-A1 | QUINAZOLINES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | RAB1A, SOS1, IQGAP1 | DDB1 2095/4885CRBN 3656/4885HSD11B1 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.